ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant

J. A. Morillas-Rodriguez1, H. Hassouna2, F. Marco-Canosa3, K. D. Brizendine1

1Infectious disease, Cleveland Clinic, Cleveland, OH, 2Infectious disease, Spectrum health, Grand rapids, MI, 3Cleveland Clinic, Cleveland, OH

Meeting: 2019 American Transplant Congress

Abstract number: A339

Keywords: Fungal infection, Lung transplantation, Prophylaxis

Session Information

Session Name: Poster Session A: Transplant Infectious Diseases

Session Type: Poster Session

Date: Saturday, June 1, 2019

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

*Purpose: Itraconazole (ITR) therapeutic drug monitoring (TDM) for prophylaxis in lung transplant recipients (LTR) is not well characterized. Our purpose was to evaluate ITR trough concentration and its association with identification of fungal pathogens.

*Methods: We conducted a retrospective study of adult LTR from 2014-2017. We collected data on clinical features, microbiology, and ITR TDM. Patients were initially administered 200mg oral solution per protocol. Association between ITR trough concentration and identified fungal pathogens was determined by comparing the incidence rate of positive bronchoalveolar lavage (BAL) fluid studies in LTR with at least 1 total ITR level ≥2 ug/mL to LTR with total ITR levels <2 ug/mL. Total ITR level was defined as the sum of ITR and Hydroxy-ITR, using Liquid Chromatography-Tandem Mass Spectrometry.

*Results: We identified 527 LTR on 388,000 days of ITR. 1,132 ITR trough concentrations were analyzed. We divided patients into 2 groups: group 1 had at least one level ≥2.0 (n=112 [21%]); and group 2 had all levels <2.0 (n=415 [79%]). There was marked inter- and intra-patient variability for both ITR and Hydroxy-ITR levels. Median ITR level at steady-state in group 1 was 2.0, significantly higher compared to 0.70 in group 2. Median duration of ITR was 730 days in group 1 and 580 days in group 2. The primary outcome was identification of a fungal pathogen in BAL fluid. 25 (22%) in group 1 were found to have a fungal pathogen compared to 127 (31%) in group 2. Median time to pathogen isolation was similar in the 2 groups: 115 vs. 90 days. Most fungal pathogens were Aspergillus species (76 vs. 67%, respectively, in groups 1 and 2). Overall rate of fungal pathogen identification was 0.39 per 1,000 patient days on ITR (95% CI 0.33-0.46). The rate in group 1 was 0.26 (95% CI 0.17-0.38), which was significantly lower than group 2 (0.43 [95% CI 0.36-0.51]). Having at least one ITR level ≥2.0 was associated with a statistically significant 39% reduction in rate of fungal pathogen identification (rate ratio 0.61 [95% CI 0.39-0.92]; p=0.02). 1-year all-cause mortality was significantly lower in group 1 (4 vs. 13% [p=0.002]).

*Conclusions: Achieving ≥1 total ITR trough concentration ≥2.0 was associated with a decrease in the rate of identifying fungal pathogens in BAL fluid of LTR and improved survival. The optimal ITR level for prophylaxis in LTR is not well defined. Based on our data, we think that the total ITR is the most appropriate measure and a level of approximately 2 could be a reasonable target.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Morillas-Rodriguez JA, Hassouna H, Marco-Canosa F, Brizendine KD. Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/target-itraconazole-trough-concentration-for-prophylaxis-in-lung-transplant/. Accessed May 11, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences